ARKG Holdings of CareDx (CDNA) - Updated Daily
GenomicsGenetic Testing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 2.57% | $431.96m |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 15 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 38 | $37.89 |
| 🎫ARK Ownership Percent | |
| 12.32% | |
| Description | |
|---|---|
| caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos | |
| Website | |
| caredx.com |
Other ETFs That Hold CDNA
Research Notes and Commentary for CDNA
No Research Notes Found for CDNA